Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1.

Molecules

Pharmacology Unit, Biomedical Sciences Department, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.

Published: May 2021

Atherosclerotic cardiovascular disease is the leading cause of death in developed countries. Therefore, there is an increasing interest in developing new potent and safe antiplatelet agents. Coumarins are a family of polyphenolic compounds with several pharmacological activities, including platelet aggregation inhibition. However, their antiplatelet mechanism of action needs to be further elucidated. The aim of this study is to provide insight into the biochemical mechanisms involved in this activity, as well as to establish a structure-activity relationship for these compounds. With this purpose, the antiplatelet aggregation activities of coumarin, esculetin and esculin were determined in vitro in human whole blood and platelet-rich plasma, to set the potential interference with the arachidonic acid cascade. Here, the platelet COX activity was evaluated from 0.75 mM to 6.5 mM concentration by measuring the levels of metabolites derived from its activity (MDA and TXB), together with colorimetric assays performed with the pure recombinant enzyme. Our results evidenced that the coumarin aglycones present the greatest antiplatelet activity at 5 mM and 6.5 mM on aggregometry experiments and inhibiting MDA levels.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161015PMC
http://dx.doi.org/10.3390/molecules26103036DOI Listing

Publication Analysis

Top Keywords

antiplatelet activity
8
antiplatelet
5
activity coumarins
4
coumarins vitro
4
vitro assays
4
assays cox-1
4
cox-1 atherosclerotic
4
atherosclerotic cardiovascular
4
cardiovascular disease
4
disease leading
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!